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Abstract
Background: Cervical cancer ranks as the first most frequent cancer among women in Benin. The major cause of
cervical cancer now recognized is persistent infection of Human Papillomavirus (HPV). In Benin there is a lack of
screening programs for prevention of cervical cancer and little information exists regarding HPV genotype
distribution.
Methods: Cervical cells from 725 women were examined for the presence of viral DNA by means of a polymerase
chain reaction (PCR) multiplex-based assay with the amplification of a fragment of L1 region and of E6/E7 region
of the HPV genome, and of abnormal cytology by Papanicolaou method. The association between HPV status and
Pap test reports was evaluated. Socio-demographic and reproductive characteristics were also related.
Results: A total of 18 different HPV types were identified, with a prevalence of 33.2% overall, and 52% and 26.7%
among women with and without cervical lesions, respectively. Multiple HPV infections were observed in 40.2% of
HPV-infected women. In the HPV-testing group, the odds ratio for the detection of abnormal cytology was 2.98
(95% CI, 1.83-4.84) for HPV positive in comparison to HPV negative women. High risk types were involved in 88%
of infections, most notably HPV-59, HPV-35, HPV-16, HPV-18, HPV-58 and HPV-45. In multiple infections of women
with cytological abnormalities HPV-45 predominated.
Conclusions: This study provides the first estimates of the prevalence of HPV and type-specific distribution among
women from Benin and demonstrates that the epidemiology of HPV infection in Benin is different from that of
other world regions. Specific area vaccinations may be needed to prevent cervical cancer and the other HPV-
related diseases.
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Background
Benin has a population of 2.22 million women aged 15
years and older who are at risk of developing cervical
cancer. Cervical cancer ranks as the first most frequent
cancer among women in Benin, and the second most
frequent cancer among women between 15 and 44 years
of age. Current estimates indicate that every year 925
women are diagnosed with cervical cancer and 616 die
from the disease [1].
There is an annual global incidence of nearly 500 000
new cervical cancer cases, with 274 000 deaths per year
[2]. More than 80% of these cases occur in developing
countries, and this percentage is expected to increase to
nearly 90% by the year 2020 [3].
In developing countries, such as Benin, there is a lack
of effective screening programs for prevention of cervi-
cal cancer. In these countries, in fact, no clinically sig-
nificant reduction in the incidence of cervical cancer has
occurred during the past three decades [2,4]. In devel-
oped countries, by contrast, there has been a major
decline in cervical-cancer mortality after the introduc-
tion of large-scale cytological testing [2]. The introduc-
tion of the Pap test into general screening programs in
the United States has reduced the incidence of advanced
forms of cervical cancer by 75% over the past few dec-
ades [5,6]. * Correspondence: fpiras@unica.it
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persistent infection of HPV [7]. HPV exists in a surpris-
ingly large number of different types: to date > 100 have
been identified and it has been anticipated that almost
200 may exist [8]. Cervical infections by approximately
15 cancer-associated (carcinogenic or high-risk) HPV
genotypes (HR-HPV) cause virtually all cervical cancers
and their immediate precursors worldwide [9].
The distribution of HPV types varies greatly across
populations and HPV surveys have been performed in
different geographical regions in order to apply appro-
priate vaccine strategies [10]. However, little information
exists regarding HPV genotype distribution in women
from developing countries at high incidence of cervical
cancer and, concerning Benin, data are not yet available
on the HPV burden in the general population [1].
In light of these considerations, the aim of this study
was to examine, through an observational study, the
HPV genotype distribution and the cervical cell cytology
among women from Benin by evaluating genital swabs
collected from 725 women undergoing voluntary screen-
ing. In addition, socio-demographic and reproductive
characteristics were related with HPV and cytological
results.
Methods
Study Population and Sample Collection
From January to September 2009 a total of 725 genital
swabs were collected from women aged from 15 to 70
years undergoing voluntary screening at Saint Luc Hos-
pital of Cotonou and Porto-Novo (south Benin), at the
Hospital of Abomey, at the St. John Catholic Hospital of
Parakou and of Lokossa (south-central Benin), at the
Hôpital de L’O r d r ed eM a l t eo fD j o u g o u ,a tS a i n tJ e a n
de Dieu Fatebenefratelli of Tanguetà, and Natitingou in
Atakora Department (north-west Benin), and at the
main maternity hospital (HOMEL, Hôpital Mère-Enfant
de la Lagune). The study protocol was approved by the
local research ethic committee, and informed consent
was obtained from all subjects according to the World
Medical Association Declaration of Helsinki. All partici-
pants were interviewed using a structured questionnaire
with respect to sociodemographic and reproductive
characteristics such as age, age at first sexual activity,
number of pregnancies, age at first menstruation, and
number of abortions. They were also instructed about
the causes of cervical cancer, signs and symptoms, pre-
vention, early detection, and treatment. Results of HPV
and cytological testing were delivered to the health cen-
tres after testing, and those with positive tests were sug-
gested for colposcopy, biopsy, and adequate treatments.
Cervical smears, suspended in ThinPrep preservative
solution, were processed for HPV types at Research
Laboratories, bcs Biotech S.p.A., Cagliari, Italy, on the
basis of the manufacturer’s instructions. In the cytologi-
cal testing, cervical cells were collected with the use of
the Ayre’s spatula (esocervix) and cytobrushes (endocer-
vix). The smears were processed in the Cytomorphology
Department laboratories of Cagliari University, Italy, and
independently evaluated by two anatomopathologists,
according to the 2001 Bethesda system [11,12].
Training
Screening was performed by doctors and auxiliary
nurse-midwives who were trained in a preventive course
using International Agency for Research on Cancer
(IARC) manuals for the collection of cervical cells for
HPV and cytological testing.
Cytology
All the women were screened for the presence of abnor-
mal cervical cytology with conventional Pap smears.
Interpretation of the cytological specimens was reported
according to the Bethesda System 2001, adopted in May
2001 and including revision statements of specimen ade-
quacy, general categorization, interpretation and result
of epithelial cell abnormalities as follows: “atypical squa-
mous cells” (ASC) divided into qualifiers of 1) ASC of
“undetermined significance” (ASC-US), and 2) “cannot
exclude high-grade squamous intraepithelial lesion”
(ASC-H); low-grade squamous intraepithelial lesion
(LSIL); high-grade squamous intraepithelial lesion
(HSIL); squamous cell carcinoma; atypical glandular
cells (AGC), with attempts to identify whether the origin
of the cells was endometrial, endocervical or unqualified;
endocervical adenocarcinoma in situ and “AGC favour
neoplastic”. Any abnormalities detected were dealt with
in compliance with guidelines updated by the Italian
Association of Colposcopy and Cervical/Vaginal Pathol-
ogy [13-17].
HPV DNA Typing
HPV DNA typing was performed by the Biochip array
genotyping test based on four major processes that
include specimen preparation, using the ProDect
® HPV
Extraction kit (bcs BIOTECH), multiplex PCR amplifica-
tion of target DNA, hybridization of amplified products
to oligonucleotide probes, and finally detection of the
amplified products by colourimetric determination,
using the ProDect
® Chip HPV Typing kit (bcs BIO-
TECH). The test system uses L1 viral region (143 bp) as
target to detect and type 14 viruses with a high-medium
oncogenic risk (HPV-16, HPV-18, HPV-31, HPV-33,
HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56,
HPV-58, HPV-59, HPV-68, HPV-73), and 5 viruses with
a low-oncogenic risk (HPV-6, HPV-11, HPV-42, HPV-
43, HPV-44). Moreover, to increase the rate and com-
plete the HPV detection, this method amplifies the E6
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negative results [18-22].
DNA extraction was carried out with the ProDect
®
HPV Extraction kit (bcs BIOTECH, Cagliari, Italy) as
follows: 3 ml of ThinPrep cytological suspension were
centrifuged at 2000 rpm for 20’; cell pellets were resus-
pended in a lysis buffer and digested with Proteinase K.
The total DNA extracted was concentrated with an
alcoholic precipitation and resuspended with 30 μlo f
Tris-EDTA buffer.
DNA amplification was performed by multiplex PCR
with the ProDect
® Chip HPV Typing kit (bcs BIO-
TECH, Cagliari, Italy): each 50 μl reaction consisted of
working mix containing MgCl2, KCl, TRIS-HCl, Taq
DNA polymerase, dNTPs, and biotinylated GP5+/GP6+,
pU-1M/pU-2R primers and b-globin primers together
with 5 μl of DNA sample. The PCR was programmed as
follows: 94°C for 2 min, and 5 cycles of 94°C for 30 sec,
50°C for 1 min, 72°C for 30 sec and 40 cycles of 94°C
for 30 sec, 45°C for 1 min, 72°C for 30 sec and finally,
at 72°C for 10 min before cooling it indefinitely at 4°C.
Hybridization to the oligonucleotide probe: denaturing
solution was added to the PCR product; all washes and
hybridization steps were undertaken in a 96-microplate
wells in which the specific probes for 19 HPV geno-
types, E6/E7 sequences, and b-globin reference were
pre-spotted [23]. The system also included a hybridisa-
tion control probe to monitor the phase of detection on
the chip, and a PCR control probe to check the phase of
amplification and extraction.
Colourimetric determination: the colour change reac-
tion was from Streptavidin-phosphatase mediated preci-
pitation of working substrate.
The Biochip reading and pattern interpretation were
performed through an automated reader and specifically
designated software (ProDect
® Bcs Biochip Reader - bcs
BIOTECH, Cagliari, Italy). Based on the microbiological
profile of the sample, different patterns appeared on the
chip, each corresponding to the type of pathogen poten-
tially present in the starting sample.
To confirm the results of Biochip typing method, the
PCR product was also sequenced using the Big Dye Ter-
minator Cycle Sequencing Kit (Applied Biosystems).
Statistical Analysis
Statistical analysis was performed by Statistical Package
for the Social Sciences 15.0 software. All variables were
expressed as absolute and relative frequencies.
The association between HPV status and Pap test
reports was evaluated by calculating crude odds ratio
(OR) by logistic regression analysis with a 95% confi-
dence interval (CI) and by Fisher’s exact test. The asso-
ciation between HPV or Pap test status and clinical-
gynaecological variables, such as number of pregnancies,
number of abortions, menopausal status, and pregnancy
status, was assessed through the c
2 test or Fisher’s exact
test (significant P value < 0.05). Mann-Whitney and
Kruskal-Wallis tests were used to analyze differences
between age at diagnoses, age at first sexual activity, age
at menarche, age at first childbirth and HPV or Pap test
status for all women.
To deal with missing data, a multiple imputation
model with fully conditional specification was used.
Results
Of the 725 women who came to the clinic study 427
had valid HPV tests, whereas 298 have no adequate
sample to HPV testing.
Viral DNA was identified in 142 of the 427 samples
(33.2%); 85 (59.8%) samples had single infection and 57
(40.2%) had multiple infection. Among HPV-positive
samples, 125 (88%) had high-risk HPV infection (Table
1).
HPV-59 and HPV-35 were the most commonly
detected types, followed by other high-risk genotypes
such as HPV-16 (17.6%), HPV-18 (14.8%), HPV-58
(13.4%), HPV-45 (9.9%), HPV-56 (8.4%), and low risk
g e n o t y p e ss u c ha sH P V - 4 2( 7 . 7 % ) ,H P V - 6a n d- 1 1( 7 % )
in women with both normal and abnormal cytology.
HPV-59 was detected both in single and multiple infec-
tions, whereas other HR-HPV types (i.e., HPV-35, HPV-
16, HPV-18, and HPV-45) were more frequently identi-
fied in multiple infections (Table 1).
Among the 427 women who had a HPV testing, 354
had both Pap test and HPV testing (Table 2). Among
the 354 women HPV DNA was found in 26.7% of 258
women with negative Pap tests and in 52% of 96 abnor-
mal Pap tests. Seventy-two ASC-US, 7 LSILs, 4 HSILs, 7
ASC-H, 6 AGC were found among the 96 women with
abnormal Pap test. Among women with both abnormal
Pap smear and HPV infection (n = 50), 96% had HR-
HPVs. In the HPV-testing group, the odds ratio for the
detection of abnormal cytology was 2.98 (95% CI, 1.83-
4.84) for HPV positive in comparison to HPV negative
women. Fisher’s exact test showed a statistically signifi-
cant correlation between HPV presence and abnormal
cytology (P < 0.0001).
HPV DNA presented in 46% of ASC-US, in 71.4% of
LSILs, in 75% of HSILs, in 57.1% of ASC-H, and in
85.7% of AGC.
Tables 3 and 4 show the genotype HPV distribution in
the single and multiple infections of the specific cytolo-
gical lesions.
The correlation between the HPV positivity or abnor-
mal cytology and most of clinical-gynaecological charac-
teristics of screened Benin women, such as number of
pregnancies, number of abortions, menopausal status,
and pregnancy status, assessed by Fisher’s exact test,
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Page 3 of 7Table 1 HPV type distribution (%) in single and multiple infections in 142 women in Benin, West Africa
HPV genotype Total infections (n = 142)
n (%)
Single infections (n = 85)
n (%)
Multiple infections (n = 57)
n (%)
P
a
High-risk
HPV-59 35 (24.65) 20 (23.53) 15 (26.32) 0.705
HPV-35 32 (22.54) 11 (12.94) 21 (36.84) 0.001
HPV-16 25 (17.61) 10 (11.76) 15 (26.32) 0.026
HPV-18 21 (14.79) 8 (9.41) 13 (22.81) 0.028
HPV-58 19 (13.38) 9 (10.59) 10 (17.54) 0.233
HPV-45 14 (9.86) 3 (3.53) 11 (19.30) 0.002
HPV-56 12 (8.45) 9 (10.59) 3 (5.26) 0.263
HPV-73 7 (4.93) 3 (3.53) 4 (7.02) 0.347
HPV-33 6 (4.23) 0 (0.00) 6 (10.53) 0.002
HPV-51 5 (3.52) 0 (0.00) 5 (8.77) 0.005
HPV-31 5 (3.52) 1 (1.18) 4 (7.02) 0.064
HPV-52 4 (2.82) 2 (2.35) 2 (3.51) 0.683
HPV-39 1 (0.70) 1 (1.18) 0 (0.00) 0.411
Low-risk
HPV-42 11 (7.75) 7 (8.24) 4 (7.02) 0.790
HPV-6 10 (7.04) 0 (0.00) 10 (17.54) 0.000
HPV-11 10 (7.04) 0 (0.00) 10 (17.54) 0.000
HPV-43 6 (4.23) 0 (0.00) 6 (10.53) 0.002
HPV-44 1 (0.70) 1 (1.18) 0 (0.00) 0.411
aSingle infection versus multiple infection, Z-test or Fisher’ s exact test.
Table 2 Prevalence of HPV types in women in Benin with normal and abnormal cytological results
Pap test and HPV performed samples (n = 354)
Normal cytology (n = 258) Abnormal cytology (n = 96)
HPV type Single infection
n (%)
Multiple infection
n (%)
Total
n (%)
Single infection
n (%)
Multiple infection
n (%)
Total
n (%)
HPV + 45 (17.4) 24 (9.3) 69 (26.7) 28 (29.2) 22 (22.9) 50 (52.1)
High-risk
HPV-59 11 (24.4) 11 (45.8) 22 (31.9) 7 (25.0) 5 (22.7) 12 (24.0)
HPV-56 6 (13.3) 0 (0.0) 6 (8.7) 3 (10.7) 2 (9.1) 5 (10.0)
HPV-16 5 (11.1) 6 (25.0) 11 (15.9) 3 (10.7) 6 (27.3) 9 (18.0)
HPV-18 4 (8.9) 4 (16.7) 8 (11.6) 3 (10.7) 5 (22.7) 8 (16.0)
HPV-35 3 (6.7) 9 (37.5) 12 (17.4) 5 (17.9) 6 (27.3) 11 (22.0)
HPV-58 3 (6.7) 5 (20.8) 8 (11.6) 2 (7.1) 2 (9.1) 4 (8.0)
HPV-45 3 (6.7) 1 (4.2) 4 (5.8) 0 (0.0) 8 (36.4) 8 (16.0)
HPV-73 1 (2.2) 2 (8.3) 3 (4.3) 2 (7.1) 2 (9.1) 4 (8.0)
HPV-39 1 (2.2) 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0)
HPV-31 1 (2.2) 1 (4.2) 2 (2.9) 0 (0.0) 3 (13.6) 3 (6.0)
HPV-33 0 (0.0) 2 (8.3) 2 (2.9) 0 (0.0) 4 (18.2) 4 (8.0)
HPV-51 0 (0.0) 3 (12.5) 3 (4.3) 0 (0.0) 2 (9.1) 2 (4.0)
HPV-52 0 (0.0) 1 (4.2) 1 (1.4) 2 (7.7) 1 (4.5) 3 (6.0)
Low-risk
HPV-42 6 (13.3) 3 (12.5) 9 (13.0) 1 (3.6) 1 (4.5) 2 (4.0)
HPV-44 1 (2.2) 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0)
HPV-6 0 (0.0) 6 (25.0) 6 (8.7) 0 (0.0) 4 (18.2) 4 (8.0)
HPV-11 0 (0.0) 6 (25.0) 6 (8.7) 0 (0.0) 4 (18.2) 4 (8.0)
HPV-43 0 (0.0) 2 (8.3) 2 (2.9) 0 (0.0) 3 (13.6) 3 (6.0)
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exact test showed that the abnormal Pap smear appears
in 27.9% of women under 36 (mean value) and 18.6% of
older ones (P = 0.01). Mann-Whitney and Kruskal-
Wallis tests showed a significant correlation between
age at diagnoses and abnormal cytology (P = 0.03). No
correlation was found between age at diagnoses and
HPV status (P = 0.28). These tests have not shown sig-
nificant correlation between HPV or Pap test status with
age at first sexual activity (P = 0.8 and P =0 . 8 3 ,r e s p e c -
tively), age at menarche (P =0 . 7 7a n dP = 0.92, respec-
tively), and age at first childbirth (P = 0.05 and P = 0.08,
respectively).
Discussion
For the first time, this study provides information on
HPV prevalence and type-specific distribution among
women from Benin undergoing voluntary screening.
The data show a very high overall prevalence of HPV
infection of 33.2% in such women. Moreover, 88% of
the Benin women’s infections presented high risk HPV
types, and 40.1% of the infections involved more than
one HPV type (2-7 types).
Most of HPV-DNA positive women analysed in this
study were infected with HPV-59, HPV-35, HPV-16,
and -18, in decreasing order. The HPV types had differ-
ent distributions in single and multiple infections. HPV-
59 was present with the same proportion in single and
multiple infections, while 36.84% of multiple infections
presented HPV-35, followed in decreasing order by
HPV-16, HPV-18 and HPV-45 (Z-test and Fisher’s exact
test).
These data on HPV type distribution in women from
Benin indicate that the epidemiology of HPV infection
in this area is different from other regions of the world
and also from those close to Benin such as Nigeria and
Burkina Faso. The prevalence of HPV genotypes in cer-
vical cytological samples varies greatly in different geo-
graphical regions [24-27]. In fact, both in women with
normal cervical cytology and in those with cervical
lesions or cancer, HPV-16 is the most common HPV
type followed by HPV-18 in Europe, Central and South
America, by HPV-52 and HPV-58 in Asia, by HPV-53
and HPV-52 in North America [28,29], HPV-31 and
HPV-35 in Nigeria [30]. In Burkina Faso HPV-52, -35
and -58 were detected as the most prevalent types in
high risk women, as observed in other African studies
[31]. These differences in the pattern of HPV type distri-
bution in countries and regions may be related to differ-
ent sexual habits and migrations of people [29,32].
The frequency of HPV in cervical cytological samples
shows a strong correlation with cervical cancer inci-
dence, but HPV-positivity may be detected in a high
rate in women with negative histology or cytology. In
this study, HPV DNA was detected in 26.7% of women
from Benin without cytological abnormalities and many
of whom harboured HPV types with very high progres-
sive potential. These are alarming data since they result
very high in comparison to those of a recent meta-ana-
lysis that estimated that the worldwide HPV prevalence
in the cervix of women with normal cytology is about
10.4% [28]. The data are similar to high values of HPV
frequency detected in Nigeria, a region that Benin
belongs to. In fact, the population-based HPV surveys
coordinated by the IARC reported that Nigeria had the
highest prevalence of all HPV types and Europe the low-
est, with nearly a 20-fold variation between Nigeria
(25.6%) and Spain (1.4%) in women without cytological
abnormalities [26,30,33].
The HPV type 16, although with different prevalence
rates, is the most common viral type, being present in
12.3%, 18.4%, 21.4% and 25.5% of HPV-positive women
without cytological lesions from Sub-Saharan Africa
(Nigeria), Asia, South America and Europe, respectively
[26]. These data show that not HPV-16 but HPV-59 is
Table 3 HPV-type distribution in single infection of
women with abnormal cytology
HPV-type No. women ASC-US ASC-H AGC LSIL HSIL
HPV-59 74 1 2 0 0
HPV-35 54 0 0 0 1
HPV-56 33 0 0 0 0
HPV-16 33 0 0 0 0
HPV-18 32 0 1 0 0
HPV-52 20 1 0 0 1
HPV-73 22 0 0 0 0
HPV-58 21 0 0 0 1
HPV-42 11 0 0 0 0
Table 4 HPV-type distribution in multiple infections of 22
women with abnormal cytology
No.
women
ASCUS No.
women
ASC-H
1 HPV-45, 35, 16, 33, 59, 58,
52
1 HPV-45, 18,
31
1 HPV-45, 16, 6, 11, 43 1 HPV-35, 59
1 HPV-45, 35, 31, 43
1 HPV-59, 51, 56, 73 AGC
1 HPV-45, 33, 43 1 HPV-18, 31
1 HPV-45, 56 1 HPV-16, 33
1 HPV-45, 58
1 HPV-45, 16 LSIL
1 HPV-16, 33 1 HPV-59, 51,
42
1 HPV-59, 73 1 HPV-16, 58
3 HPV-35, 18 3 HPV-6, 11
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cytological lesions, with a prevalence of 31.9%. Never-
theless, the HPV-35 and HPV-16, also not representing
t h ep r e v a l e n tt y p e s ,a r ep r e s e n ta tav e r yh i g hr a t ei n
normal cytological samples (17.4% and 15.9%
respectively).
As expected, in women from Benin with abnormal
Pap tests HPV DNA was detected with a high rate of
52%. The odds ratio in fact shows that HPV-infected
women run a double risk of having a cervical lesion
compared to those uninfected. HPV-59 and HPV-35 are
the most common HPV types identified in these women
with cytological lesions, followed by HPV-16, HPV-18.
In multiple infections, HPV-45 was the one mostly
detected. These findings are disturbing since previous
surveys from nearby geographically regions showed that
HPV35 and HPV45 were common in sub-Saharan
Africa women with high-grade squamous intraepithelial
lesions and squamous cell carcinoma [24-26].
Population-based data for HPV-type distribution is a
prerequisite to development of new HPV-screening tests
to predict the potential benefits of HPV vaccination and
to monitor the impact of vaccination on HPV type
replacement, but these data are limited or missing for
many world regions [26]. This study for the first time
reports the frequency of HPV infection and HPV geno-
type distribution on a female population from Benin
and shows that the most frequent HPV types are HPV-
59, HPV-35, HPV-16, HPV-18 and HPV-45 in women
with and without cytological lesions. Recently, the Food
and Drug Administration approved two HPV vaccine
(Gardasil and Cervarix) which are directed against only
HPV-6, -11, -16, and HPV-18 of the oncogenic HPV
strains [3,34]. However, even though clinical trials of
these prophylactic vaccines targeted for HPV-16 and -18
showed a considerable preventive effect for HPV infec-
tion and precancerous lesions, the cross-protection
among different HPV genotypes remains unsolved in
vaccinated women [35,36] and, despite vaccination,
other oncogenic strains, more prevalent compared to
HPV-16 and 18, as well as HPV-59, HPV-35, and HPV-
45 in Benin, would cause infections of different severity.
Moreover, the two vaccines have been documented in
clinical trials to have a durability of only 5-8 years [34]
and long-term protection after this time is unknown.
Thus, costly boosters, especially for developing coun-
tries, would be necessary to maintain immunity against
these HPV genotypes [37,38]. Therefore, the results of
this study suggest that to prevent cervical cancer and
other HPV-related diseases, the development of other
vaccines directed against genotypes more prevalent than
HPV-16 and HPV-18, detected in Benin, are needed.
The results of the association between the gynaecolo-
gical and socio-demographic characteristics and HPV
infection or Pap test results are inconsistent except for
the relation of abnormal Pap smears to young age, age
at first childbirth, and number of spontaneous abortions.
Individual sexual habits, difficult to detect in popula-
tions, are probably responsible for these data.
Conclusions
These data can be considered as nationally representa-
tive of Benin because the study analysed women from a
population living there. A major strength of this study is
the fact that it provides the first estimates of the preva-
lence of HPV among women from the general popula-
tion in Benin, showing an elevated frequency of genital
HPV infection in Benin women. Moreover, the high pre-
valence of viral types other than vaccine types should be
taken into account in developing area-specific vaccines.
These data will contribute to elucidating the epidemiol-
ogy of HPV infection across subpopulations, and it will
also be helpful in the implementation of future preven-
tion strategies.
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